As our data suggest that tumor-intrinsic CDK8 controls NK-cell immune evasion in a kinase-independent manner, CDK8/CDK19 kinase inhibitors would not suffice to reach a clinical benefit. The gene discussed is CDK19; the disease is neoplasm.